Sex as a predictor of response to cancer immunotherapy
- PMID: 30102227
- PMCID: PMC7002025
- DOI: 10.1016/S1470-2045(18)30517-5
Sex as a predictor of response to cancer immunotherapy
Conflict of interest statement
We declare no competing interests.
Comment in
-
Sex as a predictor of response to cancer immunotherapy - Authors' reply.Lancet Oncol. 2018 Aug;19(8):e380-e381. doi: 10.1016/S1470-2045(18)30535-7. Lancet Oncol. 2018. PMID: 30102230 No abstract available.
Comment on
-
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16. Lancet Oncol. 2018. PMID: 29778737
References
-
- Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol 2018; 19: 737–46. - PubMed
-
- Alexander BM, Schoenfeld JD, Trippa L. Hazards of hazard ratios-deviations from model assumptions in immunotherapy. N Engl J Med 2018; 378: 1158–59. - PubMed
-
- Hasegaw T, Claggett B, Tian L, Solomon SD, Pfeffer MA, Wei LJ. The myth of making inferences for an overall treatment efficacy with data from multiple comparative studies via meta-analysis. Stat Biosci 2017; 9: 284–97.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources